. 2009 Aug 26;114(18):3822–3830. doi: 10.1182/blood-2009-06-226332

Table 2.

Frequency and absolute numbers of circulating CD56⁺/Siglec-7⁺, CD56⁻/Siglec-7⁺, and CD56⁻/Siglec-7⁻ NK-cell subsets from HIV-1–infected patients at different stages of disease compared with those from healthy donors

Cohort	NK cells
Cohort	CD56⁺/Siglec-7⁺	CD56⁺/Siglec-7⁻	CD56⁻/Siglec-7⁻	Total
Healthy donors (n = 70)	11.1 ± 4.3 (190 ± 64)	1.1 ± 1.3 (20 ± 15)	0.8 ± 0.6 (14 ± 20)	13.3 ± 6.1 (223 ± 91)
Early HIV-1 infection (n = 21)	6.5 ± 3.3 (108 ± 71, ↓)^*	7.5 ± 3.6 (125 ± 62, ↑)^*	1.4 ± 0.9 (23 ± 19, ∼)^†	15.6 ± 12.3 (258 ± 146, ∼)^†
Chronic viremic HIV-1 infection (n = 96)	3 ± 2.1 (49 ± 25, ↓)^*	5.7 ± 3.1 (98 ± 32, ↑)^*	5.1 ± 2.1 (82 ± 38, ↑)^*	14.1 ± 5.6 (231 ± 73, ∼)^†
Chronic LTNPs (n = 27)	10.9 ± 4.8 (185 ± 46, ∼)^†	1.74 ± 1.5 (32 ± 25, ∼)^†	1.3 ± 1.1 (25 ± 16, ∼)^†	14.3 ± 6.1 (245 ± 85, ∼)^†

Results include the percentages of CD3⁻/CD19⁻/CD14⁻ NK-cell subsets within the lymphocyte population, followed by the absolute numbers of cells/μL (values in parentheses), presented as median ± SD. See also Figure 1 for gating strategy.

↑ indicates increased; ↓, decreased; and ∼, stable.

P < .001.

^†

P = not significant.